Cell-type- and tumour-type-related patterns of bcl-2 reactivity in mesenchymal cells and soft tissue tumours

Virchows Archiv

Volumn 433, Issue 3, 1998, Pages 255-260

  Miettinen, Markku ^a   Sarlomo Rikala, Maarit ^b   Kovatich, Albert J ^c  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^b UNIVERSITY OF HELSINKI   (Finland)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Bcl 2; Soft tissue tumours

Indexed keywords

PROTEIN BCL 2;

ARTICLE; DERMATOFIBROSARCOMA PROTUBERANS; DESMOID TUMOR; ESOPHAGUS CANCER; FASCIITIS; FIBROMA; HEMANGIOPERICYTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MESENCHYME; NERVE SHEATH TUMOR; NEURILEMOMA; PRIORITY JOURNAL; SOFT TISSUE CANCER; SYNOVIAL SARCOMA; UTERUS MYOMA;

FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MESODERM; PROTO-ONCOGENE PROTEINS C-BCL-2; SOFT TISSUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0031672093     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004280050244     Document Type: Article

References (27)

1. Bhargava V, Kell DL, van de Rijn M, Warnke RA (1994) Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 145:535-540
2. Bosman FT, Visser BC, Overen J van (1996) Apoptosis: pathophysiology of programmed cell death. Pathol Res Pract 192:676-683
3. Castle VP, Heidelberger KP, Bromberg J, Ou X, Dole M, Nunez G (1993) Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. Am J Pathol 143:1543-1550
4. Chen-Levy Z, Nourse J, Cleary M (1989) The bcl-2 candidate proto-oncogene product is a 24-kilodalton integral membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation. Mol Cell Biol 9:701-710
5. Chilosi M, Facchetti F, Dei Tos AP, Lestani M, Morassi ML, Martignoni G, Sorio C, Benedetti A, Morelli L, Doglioni C, Barberi M, Menestrina F, Viale G (1997) Bcl-2 expression in pleural and extrapleural solitary fibrous tumours. J Pathol (Lond) 181:362-367
6. Craig RW (1995) The bcl-2 gene family. Semin Cancer Biol 6:35-43
7. Hockenberry D, Nunez G, Milliman C, Schrieber R, Korsmeyer S (1990) Bcl2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334-336
8. Hockenberry D, Zutter M, Mickey W, Nahm M, Korsmeyer S (1991) BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88: 6961-6965
9. Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang HG, Reed J (1994) Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol 145:3323-1336
10. LeBrun DP, Warnke RA, Cleary ML (1993) Expression of bcl-2 in fetal tissues suggests a role in morphogenesis. Am J Pathol 142:743-753
11. Lu QL, Poulsom R, Wong L, Hanby AM (1993) Bcl-2 expression in adult and embryonic nonhematopoietic tissues. J Pathol (Lond) 169:431-437
12. Manetto V, Lorenzini R, Cordon-Cardo C, Krajewski S, Rosai J, Reed JC, Eusebi V (1997) Bcl-2 and Bax expression in thyroid tumours. An immunohistochemical and Western blot analysis. Virchows Arch 430:125-130
13. Miettinen M, Virolainen M, Sarlomo-Rikala M (1995) Gastrointestinal stromal tumours - value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol 19:207-216
14. Nakanishi H, Ohsawa M, Naka N, Uchida A, Ochi T, Aozasa K (1997) Immunohistochemical detection of bcl-2 and p53 proteins and apoptosis in soft tissue sarcoma: their correlations with prognosis. Oncology 54:238-244
15. Oltvai ZN, Milliman CL, Kosrmeyer SJ (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609-619
16. Pezzella F, Gatter K (1995) What is the value of bcl-2 protein detection for histopathologists? Histopathology 26:89-93
17. Pezzella F, Tse G, Cordell J, Pulford K, Gatter KC, Mason DY (1990) Expression of the bcl2 oncogene protein is not specific for the t (14;18) chromosomal translocation. Am J Pathol 137:225-232
18. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, Harris A, Gatter KC, Mason DY (1993) bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 329:690-694
19. Reed J, Tsujimoto Y, Alperts J, Croce C, Nowell P (1987) Regulation of bcl-2 proto-oncogene expression during normal human lymphocyte proliferation. Science 236:1295-1299
20. Reed JC (1994) Bcl-2 and the regulation of programmed cell death J Cell Biol 124:1-6
21. Reed JC, Meister L, Tanaka S, Cuddy M, Yum S, Geyer C, Pleasure D (1991) Differential expression of bcl-2 protooncogene in neuroblastoma and other human tumour cell lines of neural origin. Cancer Res 51:6529-6538
22. Soini Y, Pääkkö P (1996) Bcl-2 is preferentially expressed in tumours of muscle origin hut is not related to p53 expression. Histopathology 28:141-145
23. Swanson PH, Humphrey PA, Dehner LP (1993) Immunoreactivity for bcl-2 protein in peripheral primitive neuroectodermal tumours. Appl Immunohistochem 1:182-187
24. Tsujimoto Y, Croce CM (1986) Analysis of the structure, transcripts and protein products of the bcl-2, the gene involved in follicular lymphoma. Proc Natl Acad Sci USA 83:5214-5218
25. Van de Rijn M (1994) CD34: A review. Applied immunohistochemistry 2:71-80
26. Vaux DL (1993) Toward an understanding of the molecular mechanisms of physiological cell death. Proc Natl Acad Sci USA 90:786-789
27. Zhang KZ, Westberg JA, Hölttä E, Andersson LC (1996) Bcl-2 regulates neural differentiation. Proc Natl Acad Sci USA 93:4504-4508